PMID- 26545468
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20211203
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 36
IP  - 6
DP  - 2015 Nov-Dec
TI  - Improved therapeutic effectiveness by combining recombinant p14(ARF) with 
      antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.
PG  - 763-71
LID - S0196-0709(15)00165-9 [pii]
LID - 10.1016/j.amjoto.2015.07.012 [doi]
AB  - PURPOSE: The tumor suppressor p14(ARF) and proto-oncogene epidermal growth factor 
      receptor (EGFR) play important roles in the development of laryngeal squamous 
      cell carcinoma (LSCC). This study was aimed to determine whether combining 
      recombinant p14(ARF) with antisense complementary DNA of EGFR could improve the 
      therapeutic effectiveness in LSCC. MATERIALS AND METHODS: After human larynx 
      cancer cells (Hep-2) were infected with recombinant adenoviruses (Ad-p14(ARF) and 
      Ad-antisense EGFR) together or alone in vitro, the proliferation and cell cycle 
      distribution of Hep-2 cells were detected by MTT assay and flow cytometer 
      analysis, respectively. Furthermore, the antitumor effects of recombinant 
      adenoviruses together or alone on Hep-2 xenografts were examined in vivo. The 
      levels of p14(ARF) and EGFR expressed in Hep-2 cells and xenografts were 
      determined by western blot assay. RESULTS: Ad-p14(ARF) combining with 
      Ad-antisense EGFR markedly inhibited the Hep-2 proliferation compared with alone 
      (P=0.001, P=0.002 respectively). Combination of Ad-p14(ARF) and Ad-antisense EGFR 
      led to the proportion of Hep-2 cells in G0/G1 phases increased by up to 86.9%. 
      The down-expression of EGFR protein and overexpression of p14(ARF) protein were 
      observed in vitro and in vivo, and this effect was preserved when Ad-p14(ARF) was 
      combined with Ad-antisense EGFR. Besides, Ad-p14(ARF) plus Ad-antisense EGFR 
      significantly (P<0.05) increased the antitumor activity against Hep-2 tumor 
      xenografts comparing with Ad-p14(ARF) or Ad-antisense EGFR alone. CONCLUSION: 
      Combination Ad-p14(ARF) with Ad-antisense EGFR significantly increased the 
      antitumor responses in LSCC. An effectively potential gene therapy to prevent 
      proliferation of LSCC was provided.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Liu, Feng
AU  - Liu F
AD  - West China School of Medicine, West China Hospital, Sichuan University Department 
      of Otorhinolaryngology, Chengdu, People's Republic of China.
FAU - Du, JinTao
AU  - Du J
AD  - West China School of Medicine, West China Hospital, Sichuan University Department 
      of Otorhinolaryngology, Chengdu, People's Republic of China.
FAU - Xian, Junming
AU  - Xian J
AD  - West China School of Medicine, West China Hospital, Sichuan University Department 
      of Otorhinolaryngology, State Key Laboratory of Biotherapy, Chengdu, People's 
      Republic of China. Electronic address: fxjming@163.com.
FAU - Liu, Yafeng
AU  - Liu Y
AD  - West China School of Medicine, West China Hospital, Sichuan University Department 
      of Otorhinolaryngology, Chengdu, People's Republic of China.
FAU - Liu, Shixi
AU  - Liu S
AD  - West China School of Medicine, West China Hospital, Sichuan University Department 
      of Otorhinolaryngology, Chengdu, People's Republic of China.
FAU - Lin, Yan
AU  - Lin Y
AD  - Department of Otorhinolaryngology, the First Affiliated Hospital of Kunming 
      Medical College, Kunming, China.
LA  - eng
PT  - Journal Article
DEP - 20150805
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (DNA, Antisense)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Tumor Suppressor Protein p14ARF)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Carcinoma, Squamous Cell/*pathology/therapy
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - DNA, Antisense/*genetics
MH  - ErbB Receptors/*genetics
MH  - Genetic Therapy
MH  - Genetic Vectors
MH  - Humans
MH  - Laryngeal Neoplasms/*pathology/therapy
MH  - Proto-Oncogene Mas
MH  - Transfection
MH  - Tumor Suppressor Protein p14ARF/*genetics
EDAT- 2015/11/08 06:00
MHDA- 2016/08/20 06:00
CRDT- 2015/11/08 06:00
PHST- 2015/05/29 00:00 [received]
PHST- 2015/07/15 00:00 [revised]
PHST- 2015/07/31 00:00 [accepted]
PHST- 2015/11/08 06:00 [entrez]
PHST- 2015/11/08 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
AID - S0196-0709(15)00165-9 [pii]
AID - 10.1016/j.amjoto.2015.07.012 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2015 Nov-Dec;36(6):763-71. doi: 10.1016/j.amjoto.2015.07.012. 
      Epub 2015 Aug 5.